Metastatic Cancer trials recruiting in Texas

All Metastatic Cancer trials nationally

Cities in Texas

Recruiting trials in Texas

• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
  NCT06022029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Flower Mound, Houston
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Irving, San Antonio
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
  NCT05422911 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Texas: Houston
• Comprehensive Outcomes for After Cancer Health
  NCT05349227 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
  NCT05267626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Houston, San Antonio
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
  NCT04900818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Texas: Austin, Bedford, Dallas, Houston